NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV)
APHP241595
Phase 2 small_molecule active
Quick answer
NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV) for The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours. is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active